Cancers exhibit a mutator phenotype: clinical implications.

Malignancies are characterized by mutations. We have hypothesized that the thousands of mutations in most human cancers do not result from the low mutation rates exhibited by normal human cells. Instead, cancer cells express a mutator phenotype (i.e., the mutation rate in the cancer cells is much greater than that in normal cells). We consider the following points: (a) Mutations in genes that govern genetic stability could be the cause of a mutator phenotype exhibited by human cancers. (b) A mutator phenotype increases the efficiency of acquiring mutations including those associated with cancer. (c) Recent experimental evidence indicates that human tumors contain a vast array of both clonal mutations and nonexpanded (random) mutations. (d) The presence of nonexpanded mutations in tumors has fundamental clinical implications for cancer risk assessment, grading, and prognosis including the rapid emergence of resistance to chemotherapeutic agents. Lastly, (e) if a mutator phenotype drives carcinogenesis, drugs that target mutator pathways might prevent cancer by delay.

[1]  J. Bielas,et al.  LOH-proficient embryonic stem cells: a model of cancer progenitor cells? , 2007, Trends in genetics : TIG.

[2]  D. Lin,et al.  Fen1 mutations result in autoimmunity, chronic inflammation and cancers , 2007, Nature Medicine.

[3]  L. Secker-Walker.  Catalog of Chromosome Aberrations in Cancer , 1996, British Journal of Cancer.

[4]  M. Mendelsohn,et al.  Multi-mutational model for cancer based on age-time patterns of radiation effects: 2. Biological aspects , 1997 .

[5]  K. Eckert,et al.  DNA Polymerases and Human Diseases , 2006, Radiation research.

[6]  L. Loeb,et al.  Efficiency of carcinogenesis with and without a mutator mutation , 2006, Proceedings of the National Academy of Sciences.

[7]  C. Klein,et al.  Systemic Cancer Progression and Tumor Dormancy: Mathematical Models Meet Single Cell Genomics , 2006, Cell cycle.

[8]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[9]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[10]  Kyungjae Myung,et al.  Maintenance of Genome Stability in Saccharomyces cerevisiae , 2002, Science.

[11]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[12]  Juno Choe,et al.  Protein tolerance to random amino acid change. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Duesberg,et al.  Genetic instability of cancer cells is proportional to their degree of aneuploidy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[15]  K. Loeb,et al.  Multiple mutations and cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Balmain,et al.  How many mutations are required for tumorigenesis? implications from human cancer data , 1993 .

[17]  L. Loeb,et al.  Errors in DNA replication as a basis of malignant changes. , 1974, Cancer research.

[18]  R. Albertini,et al.  In vivo somatic mutations in humans: measurement and analysis. , 1990, Annual review of genetics.

[19]  Max S Wicha,et al.  Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.

[20]  B. Vogelstein,et al.  Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. , 1995, Oncogene.

[21]  L. Loeb,et al.  Negative Clonal Selection in Tumor Evolution , 2005, Genetics.

[22]  J Piper,et al.  Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[24]  R. Kolodner,et al.  Suppression of genome instability by redundant S-phase checkpoint pathways in Saccharomyces cerevisiae , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Armitage,et al.  The age distribution of cancer and a multi-stage theory of carcinogenesis , 1954, British Journal of Cancer.

[26]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[27]  L. Foulds.  The experimental study of tumor progression: a review. , 1954, Cancer research.

[28]  J. Coxhead,et al.  Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Klein.  Single cell amplification methods for the study of cancer and cellular ageing , 2005, Mechanisms of Ageing and Development.

[30]  Tom Lenaerts,et al.  Dynamics of chronic myeloid leukemia under nilotinib therapy , 2010 .

[31]  S. Knuutila,et al.  DNA copy number changes in development and progression in leiomyosarcomas of soft tissues. , 1998, The American journal of pathology.

[32]  Giovanni Parmigiani,et al.  Prevalence of somatic alterations in the colorectal cancer cell genome , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Juno Choe,et al.  Highly Tolerated Amino Acid Substitutions Increase the Fidelity of Escherichia coli DNA Polymerase I* , 2007, Journal of Biological Chemistry.

[34]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[35]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[36]  A. Knudson,et al.  Model for the incidence of embryonal cancers: application to retinoblastoma. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Bielas,et al.  Quantification of random genomic mutations , 2005, Nature Methods.

[38]  C. Vaquero,et al.  Transcriptional and post‐transcriptional regulation of TcR, CD4 and CD8 gene expression during activation of normal human T lymphocytes. , 1990, The EMBO journal.

[39]  C. Griffin,et al.  Genetic analysis of ovarian germ cell tumors by comparative genomic hybridization. , 1998, Cancer research.

[40]  R. Lenski,et al.  Evolution of high mutation rates in experimental populations of E. coli , 1997, Nature.

[41]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[42]  Ian Tomlinson,et al.  Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog , 1999, Nature medicine.

[43]  Andrew D. Yates,et al.  A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer , 2005, Nature Genetics.

[44]  D. Birnbaum,et al.  Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. , 1997, Cancer research.

[45]  J. Stringer,et al.  Embryonic stem cells and somatic cells differ in mutation frequency and type , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[47]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Lawrence D True,et al.  Human cancers express a mutator phenotype , 2006, Proceedings of the National Academy of Sciences.

[49]  P. Nowell,et al.  Karyotypic evolution in human malignant melanoma. , 1986, Cancer genetics and cytogenetics.

[50]  J. Cairns.  The origin of human cancers , 1981, Nature.

[51]  Robert A Beckman,et al.  Genetic instability in cancer: theory and experiment. , 2005, Seminars in cancer biology.

[52]  C. Sawyers,et al.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. , 2007, The Journal of clinical investigation.

[53]  Amanda G Paulovich,et al.  When Checkpoints Fail , 1997, Cell.

[54]  W. Bodmer,et al.  Commentary How Many Mutations in a Cancer , 2002 .

[55]  A. Velázquez,et al.  Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[56]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. , 1993, Cell.

[57]  M. Perucho.  Cancer of the microsatellite mutator phenotype. , 1996, Biological chemistry.

[58]  M. Tagawa,et al.  Advances in Brief DNA Polymerase k , Implicated in Spontaneous and DNA Damage-induced Mutagenesis , Is Overexpressed in Lung Cancer 1 , 2001 .